HIV and Cardiac diseases
The presentation of Combinational Antiretroviral Treatment (cART) has significantly diminished mortality among the HIV-infected patients. In this setting, cardiovascular disease (CVD) has turned into a main source of morbidity and mortality. Compared with the general population, higher rates of Myocardial Infarction (MI) and also a high predominance of subclinical coronary atherosclerosis have been found in the HIV-infected population. It has been proposed that in HIV-contaminated patients, the atherosclerotic burden did not depend exclusively on cardiovascular hazard factors. The interaction of different components chronic inflammation, effects of cART or immune activation after initiation of cART may incline to quickened and expanded danger of CVD. Effective treatments are accessible today to diminish CVD in high risk patients, and in this way early recognition of subclinical coronary atherosclerosis is vital. However the components behind the advancement of CVD in HIV-contaminated patients may may limit the usefulness of the traditional noninvasive screening tools for CVD used in the general population.
Edelweiss Journal of AIDS journal is a Peer reviewed journal maintaining high standards of scientific excellence and its editorial board ensures a thorough review process.
PDF
